CUV
Fiscal year ends June Quarters are offset from the calendar — Q1 is Jul–Sep

Clinuvel Pharmaceuticals Limited is a pharmaceutical company focused on developing and commercializing treatments for acute and chronic medical conditions affecting the skin and central nervous system. The company's primary business segment involves the development of melanocortin-based therapies, with its flagship product SCENESSE (afamelanotide) approved for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP) in Europe and the United States. Clinuvel is currently advancing clinical programs for vitiligo, including the Phase III study CUV105 and the design of the pivotal CUV107 study, as well as pursuing regulatory approvals for NEURACTHEL Instant for variegate porphyria. The company also operates a PhotoCosmetics segment, offering skincare products such as CYACÊLLE and the M-lines, which utilize the company's expertise in photoprotection and DNA repair. Clinuvel serves markets in North America, Europe, and Latin America, with distribution partners in the U.S., Canada, Colombia, and Argentina. The company was founded in 1999 when an Australian team acquired the rights to afamelanotide, and it lists its American Depositary Shares on the Nasdaq Stock Market.

Summarised from the company's own disclosures, fiscal year ended Jun 2026

Industry Pharmaceuticals, Biotechnology & Life Sciences Homepage clinuvel.com
Sector Healthcare IR page clinuvel.com/investor
Tags
photomedicine, melanocortins, erythropoietic protoporphyria, vitiligo, variegate porphyria, photo-cosmetics, peptide drug delivery, central nervous system, skin disorders, rare diseases, SCENESSE, afamelanotide, NEURACTHEL Instant, CYACÊLLE, M-lines, PRÉNUMBRA, VLRX-L, Valentech, Diligens Salud SA
Press page clinuvel.com/investor/asx-announcements

Metrics

Valuation  
Market cap A$ 385.722M
Market cap (USD) $ 259.641M
P/E 10.13
PEG —
P/BV 1.33
P/S 4.37
P/OCF 10.45
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE —
ROI —
ROIC —
Profit margin —
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score 36.4%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026
Revenue 64.315M
Net profit 23.178M
Free cash flow 11.849M

Filed figures

Figure Jun 2024 Jun 2025 Jun 2026
Balance sheet detail
Trade receivables (USD) 17.5M 17.7M 16.2M
↳ YoY growth +1.4% -8.8%
Lease liabilities (USD) — 332,721 1.34M
Cash and deposits (USD) — 18.1M 13.9M
Intangible assets (USD) — 120,331 127,892
Right-of-use assets (USD) — 314,162 1.36M
Cash flow detail
Operating cash flow (USD) 23.8M 27.3M 12.9M
Purchases of property, plant and equipment (USD) -3.65M -190,593 -1.06M
Change in receivables (cash effect) (USD) -2.92M 198,681 1.73M
Change in inventories (cash effect) (USD) -728,747 1.21M 1.32M
Dividends paid (cash effect) (USD) -1.59M -1.69M -1.67M
Share buybacks (cash effect) (USD) -497,659 -173,965 —
Income taxes paid (cash effect) (USD) -10.3M -10.2M -16.2M
Share-based compensation (USD) 4.07M 1.3M 1.59M
Operating cash flow before change in receivables (USD) 26.7M 27.1M 11.2M
Free cash flow (OCF - PPE - intangibles) (USD) 20.1M 27.1M 11.8M
Income detail
Research and development expense (USD) 9.99M 13.2M 12.2M
Total comprehensive income (USD) 22.6M 22.3M 32M
Comprehensive income to owners (USD) 22.6M 22.3M 32M
Reported Oct 30, 2026 Oct 30, 2026 Oct 30, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Change in substantial holding Bull 0 Bear 0 Routine
Change in substantial holding - Updated Bull 0 Bear 0 Routine
Chair address Bull 0 Bear 0 Routine

Prompts

Clinuvel Pharmaceuticals Limited (ticker CUV), listed in Australia.

Company History

Date Change Detail
— Former tickers CLVLY

ETFs Holding Clinuvel Pharmaceuticals Limited

ETF Weight in ETF Shares Market value As of
AVDS 0.01% 7,426 $ 37.843K Nov 16, 2026
DFIS 0.00% 53,540 $ 278.56K Nov 12, 2026
DFIC 0.00% 46,696 $ 242.952K Nov 12, 2026
DISV 0.00% 8,242 $ 42.882K Nov 12, 2026
DFAI 0.00% 24,698 $ 128.5K Nov 12, 2026
DFAX 0.00% 10,919 $ 56.81K Nov 12, 2026
AVDV 0.00% 484 $ 2,466.50 Nov 16, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
CUV canonical Common share — AU asx 7.24 AUD 2026-11-19
CUVL Common share — US nasdaq 5.96 USD 2026-09-30